NewGen Therapeutics Inc.
This article was originally published in Start Up
NewGen Therapeutics Inc. aims to exploit weaknesses in the intellectual property protecting certain cancer drugs that already are blockbusters or that appear destined to be highly successful in coming years. The plan is to create functionally improved versions of valuable cancer drugs and develop them as treatments for specific subsets of patients likely to respond well.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.